What is Heru?
Heru operates at the intersection of advanced medical diagnostics and artificial intelligence, focusing on the development of wearable technology designed to revolutionize vision testing. By replacing traditional, bulky diagnostic equipment with portable, software-driven solutions, the company addresses critical inefficiencies in clinical workflows. Heru's market position is defined by its commitment to democratizing access to high-quality eye care, utilizing augmented reality to provide clinicians with precise, actionable data. This disruptive model has garnered attention from key industry stakeholders, positioning the firm as a pivotal player in the digital health transformation currently reshaping the medical device landscape.
How much funding has Heru raised?
Heru has raised a total of $32.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$30M
Angel/Seed (2020): $2.7M with participation from Maurice R. Ferre and Frederic H. Moll
Series A (2021): $30M led by Maurice R. Ferre, M.D., Krillion Ventures, Frederic H. Moll, M.D., SoftBank Ventures Opportunity Fund, and D1 Capital Partners
Key Investors in Heru
Krillion Ventures
Krillion Ventures is a Miami-based venture capital fund that invests in early stage technology companies focused on healthcare, financial services, and real estate, seeking to partner with innovative entrepreneurs who challenge the status quo.
D1 Capital Partners
D1 Capital Partners is a diversified investment firm with a long history of global operations, focusing on sustainable business relations and ethical governance across sectors including energy, technology, and trade.
Maurice R. Ferre, M.D.
A prominent figure in the medical technology space, Dr. Ferre provides strategic backing and industry expertise to high-growth healthcare ventures.
What's next for Heru?
With the recent capital injection, Heru is expected to prioritize the scaling of its diagnostic platform and the expansion of its clinical footprint. The company's roadmap likely includes aggressive R&D initiatives to enhance its software capabilities and broaden the scope of its vision augmentation tools. As Heru moves deeper into the enterprise-level market, the focus will shift toward securing strategic partnerships with healthcare providers and integrating its technology into standard clinical practices. This growth trajectory underscores the company's ambition to set a new benchmark for diagnostic accuracy and patient-centric care in the global ophthalmology market.
See full Heru company page
